Peptide C1s Inhibitors Balancing Selectivity and Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for pharmaceutically acceptable compounds to inhibit the complement system, particularly the C1 esterase, to treat disorders mediated by dysfunctional complement activity, including those arising from medical treatments or procedures.
Innovation Solution
Development of compounds with improved C1s inhibiting activity, classical pathway hemolysis inhibition, Caco-2 permeability, oral bioavailability, and metabolic stability, formulated as pharmaceutical compositions to treat complement-mediated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to inhibit C1s, then complement-mediated disorders are treated, but selectivity over other proteases (such as MASP-2) must be maintained
Solution Approach 1:
The compound incorporates specific structural features (sulfonamide or sulfonilurea groups combined with heteroaryl moieties) that create localized interaction zones within the protease active site. These localized chemical properties enable selective binding to C1s while excluding other proteases like MASP-2, achieving both high inhibitory activity and selectivity simultaneously
Solution Approach 2:
The patent optimizes specific molecular parameters including the heteroaryl ring type (pyridine, pyrimidine, triazole, etc.), substitution patterns, and sulfonamide/sulfonilurea positioning to fine-tune the compound's electrostatic and steric properties. These parameter adjustments enhance affinity for C1s while reducing off-target binding to other proteases
2Reliability
If compounds are optimized for C1s inhibition, then hemolysis is inhibited, but oral bioavailability and metabolic stability must also be improved
Solution Approach 1:
The compound's physicochemical parameters are optimized by selecting specific heteroaryl groups and substitution patterns that balance polarity, molecular weight, and hydrogen bonding capacity. These changes improve oral absorption while maintaining C1s inhibitory activity and hemolysis protection
Solution Approach 2:
The molecule combines multiple functional elements (heteroaryl core, sulfonamide/sulfonilurea group, various substituents) into a composite structure where each component contributes to different properties: the core provides binding affinity, while substituents modulate metabolic stability and bioavailability
3Reliability
If compounds are designed for high C1s selectivity, then specific complement pathway inhibition is achieved, but permeability (Caco-2) must also be improved
Solution Approach 1:
The compound's lipophilicity and molecular size parameters are adjusted through selection of specific heteroaryl groups and alkyl/alkoxy substituents. These changes enhance membrane permeability across Caco-2 cells while preserving the molecular features required for selective C1s binding
Data Source
AI summary
This disclosure provides peptide based compounds, compositions, and methods to treat medical disordeds, such as complement-mediated disorders, including complement C1s-mediated disorders, such as acute antibody-mediated rejection, amyotrophic lateral sclerosis, autoimmune blistering disease, bullous pemphigoid, geographic atrophy, or Guillain-Barre Syndrome, comprising administering to a subject in need thereof a therapeutically effective amount of the compound.